SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
BOLT WILLIAM J
(Last) (First) (Middle)
C/O ABIOMED, INC.
22 CHERRY HILL DRIVE
(Street)
DANVERS MA 01923
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ABIOMED INC [ ABMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, QA and Regulatory Affairs
3. Date of Earliest Transaction (Month/Day/Year)
07/06/2011
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $.01 par value 07/06/2011 M 9,500 A $6.75 104,287(7) D
Common Stock, $.01 par value 07/06/2011 S 9,500(8) D $17.0008(9) 94,787(7) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)(2) $15.563 06/28/2004(1) 06/28/2010 Common Stock 40,000 40,000 D
Stock Option (right to buy)(3) $24.12 06/22/2005(1) 06/22/2011 Common Stock 25,000 25,000 D
Stock Option (right to buy)(3) $6.75 07/06/2011 M 9,500 06/25/2004(1) 06/25/2012 Common Stock 9,500 $0 40,500 D
Stock Option (right to buy)(2) $5.11 06/25/2005(1) 06/25/2013 Common Stock 16,000 16,000 D
Stock Option (right to buy)(3) $12.3 07/01/2005(4) 07/01/2014 Common Stock 18,000 18,000 D
Stock Option (right to buy)(3) $9.36 06/08/2006(4) 06/08/2015 Common Stock 30,000 30,000 D
Stock Option (right to buy)(3) $13.57 06/01/2007(4) 06/01/2016 Common Stock 20,000 20,000 D
Stock Option (right to buy)(3) $11.27 05/30/2008(4) 05/30/2017 Common Stock 8,000 8,000 D
Stock option (right to buy)(3) $13.8 05/23/2009(4) 05/23/2018 Common Stock 9,666 9,666 D
Stock Option (right to buy)(5) $5.86 05/28/2010(4) 05/28/2019 Common Stock 50,000 50,000 D
Stock Option (right to buy)(5) $5.86 03/31/2010(6) 05/28/2019 Common Stock 18,000 18,000 D
Stock Option (right to buy)(5) $10.03 06/03/2011(4) 06/03/2020 Common Stock 30,000 25,000 D
Explanation of Responses:
1. Options were fully exercisable on the date shown.
2. Grant to reporting person of this option to buy the number of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 1998 Equity Incentive Plan.
3. Grant to reporting person of this option to buy the number of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2000 Stock Incentive Plan.
4. These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
5. Grant to reporting person of this option to buy the number of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
6. These options became fully exerciseable on March 31, 2010.
7. Includes 9,000 shares represented by a performance share award for restricted stock units pursuant to which one third of the shares will be issued to the reporting person on each of May 26, 2012, May 26, 2013 and May 26, 2014, so long as he continues to be employed by the issuer on the vesting dates.
8. Sale of common stock pursuant to reporting owner's 10(b)5-1 plan.
9. This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $17.0000 and $17.0057. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
/s/ Ian W. McLeod (by power of attorney) 07/08/2011
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.